![\"\"](\"https:\/\/touchime.org\/wp-content\/uploads\/sites\/21\/2022\/11\/LinkedIn_Facebook_1080x1920-9-1-1-1024x576.png\")
<\/p>\n<\/p>\n
Crohn\u2019s disease and ulcerative colitis are types of chronic inflammatory bowel disease (IBD) \u2013 a long-term inflammation of the gut that affects men and women.<\/p>\n
Crohn\u2019s disease is most prevalent in women, whilst ulcerative colitis is generally more common in men (TH<\/span><\/a>). Both conditions have a reported hereditary link, with around 1 in 4 people with IBD<\/a><\/span> having a family history of the disease.<\/p>\n
WATCH<\/strong>: Dr. Gil Y Melmed on the health burden and available therapies for Crohn\u2019s disease and colitis<\/a><\/span><\/p>\n
That said, often symptoms and their impact on quality of life can be managed.<\/p>\n
Crohn\u2019s and colitis symptoms include:<\/p>\n
There are a number of treatments available to manage both conditions. Current therapies include anti-inflammatory medication, immunosuppressives, antibiotics or surgery (including colon or partial intestine removal). There are also a string of new therapies that are currently under clinical investigation.<\/p>\n
WATCH: <\/strong>Prof. Jean-Frederic Colombel discusses the efficacy and safety findings from the U-EXCEED study investigating the JAK inhibitor, upadacitinib in moderate to severe Crohn\u2019s disease<\/a><\/span><\/p>\n
WATCH:<\/strong> Dr Noa Krugliak Cleveland discusses the impact of early initiation of the integrin receptor antagonist, vedolizumab, in ulcerative colitis<\/a><\/span>.<\/p>\n
WATCH:<\/strong> Prof. Marla C. Dubinsky discusses the LUCENT-2 study investigating the IL-23 inhibitor, mirikizumab, as a maintenance therapy in moderate to severe ulcerative colitis Part 1<\/a><\/span> | Part 2<\/a><\/span><\/p>\n
When it comes to the typical age of diagnosis, it generally differs for men and women; men are often diagnosed later in life than women \u2013 women are frequently treated sooner \u2013 meaning men are at higher risk of developing other conditions<\/span><\/a>.<\/p>\n
WATCH:<\/strong> Dr Vipul Jairath discusses two treatment algorithms designed to reduce the risk of Crohn\u2019s disease related complications (REACT-2 trial)<\/a><\/span><\/p>\n
In the UK, 1 in 4 people are diagnosed before they turn 30<\/a><\/span> \u2013 and 1 in 123 people already have Crohn\u2019s or colitis<\/a><\/span>. Worldwide, IBD affects an estimated 10 million people, though experts predict this may be higher, especially if other western countries have similar ~1% prevalence rates to those reported in the UK and US<\/a><\/span> (in the UK, for instance, someone is diagnosed with Crohn\u2019s or colitis every 30 minutes<\/span><\/a>).<\/p>\n
However, as Editorial Board member, Dr. Gil Y Melmed (Cedars-Sinai, Los Angeles, CA, USA) highlights<\/a><\/span>, people who suffer with Crohn\u2019s or colitis have symptoms that are invisible to the passer-by:<\/p>\n
To help change that narrative, 1-7 December is <\/strong>Crohn’s and Colitis Awareness Week<\/strong><\/a><\/span> (#IBDvisible)<\/strong><\/p>\n
Learn more by delving into our educational content around inflammatory bowel diseases<\/a><\/span>.<\/p>\n
Alternatively, you can get in touc<\/span>h<\/a> to find out how you could benefit from our educational activities.<\/p>\n